We may earn an affiliate commission when you visit our partners.

Drug Discovery

Save
May 1, 2024 Updated November 14, 2026 21 minute read

Drug discovery is the intricate and lengthy process by which new candidate medications are identified, developed, and ultimately approved for therapeutic use. It's a multidisciplinary field that sits at the intersection of biology, chemistry, pharmacology, and medicine, striving to understand diseases at a molecular level and find innovative ways to combat them. The journey of a drug from an initial idea to a patient's bedside is a complex and highly regulated endeavor, often spanning over a decade and involving substantial investment.

The process typically begins with identifying a "target"—often a protein or a gene—that plays a crucial role in a disease. Scientists then search for or design molecules that can interact with this target to produce a desired therapeutic effect. This search can involve screening vast libraries of chemical compounds, utilizing computational models, or even harnessing the power of natural products. Once promising "hits" are found, they undergo rigorous optimization and testing to ensure they are safe and effective before they can even be considered for human trials. The potential to alleviate suffering and improve human health is a powerful motivator in this field. Furthermore, the intellectual challenge of solving complex biological puzzles and the opportunity to work with cutting-edge technologies make drug discovery an engaging and exciting area for many.

Introduction to Drug Discovery

This section will lay the groundwork for understanding the multifaceted world of drug discovery. We will explore what the field entails, how it has evolved, who the major players are, and its profound impact on our lives.

Definition and Scope of Drug Discovery

Path to Drug Discovery

Take the first step.
We've curated 24 courses to help you on your path to Drug Discovery. Use these to develop your skills, build background knowledge, and put what you learn to practice.
Sorted from most relevant to least relevant:

Share

Help others find this page about Drug Discovery: by sharing it with your friends and followers:

Reading list

We've selected 17 books that we think will supplement your learning. Use these to develop background knowledge, enrich your coursework, and gain a deeper understanding of the topics covered in Drug Discovery.
Authored by the inventor of Lyrica (pregabalin), Silverman and Holladay's masterwork elucidates receptor-ligand binding energetics, enzyme inhibition kinetics, bioisosterism, prodrug design, and metabolic biotransformations from physical organic chemistry principles.
Tracing the complete pipeline from target validation and high-throughput screening through ADME/PK optimization, GLP toxicology, biologics, and intellectual property strategy, Blass provides an authoritative roadmap for industry newcomers and academic translational scientists.
Academic chemistry courses rarely prepare scientists for how industrial project teams triage hit series, navigate patent claims, or collaborate with DMPK and formulation groups. Rydzewski demystifies day-to-day operational realities inside biotech and big pharma.
High attrition rates in preclinical and Phase I/II pipelines demand rigorous portfolio governance, go/no-go target product profiles, and translational biomarkers. Moos, Munk, and Miller examine R&D productivity metrics and AI-enabled workflow acceleration.
Chronicling the chemical lineage of every major therapeutic class—from alkaloid isolation and coal-tar dyes to beta-blockers, statins, and kinase inhibitors—Sneader reveals how serendipity, structural pharmacophores, and mechanistic insight intertwined across centuries.
Celebrated for its crystal-clear diagrams of GPCR signaling, structure-activity relationships (SAR), combinatorial synthesis, and case studies on cimetidine and imatinib, Patrick's seventh edition is the premier university textbook for medicinal chemistry.
High-quality chemical starting points determine whether a discovery campaign succeeds or stalls in lead optimization. Rankovic and Morphy compare fragment-based screening, virtual docking, DNA-encoded libraries, and knowledge-based chemotype hopping.
Potent in vitro target binding means nothing if a compound suffers from poor aqueous solubility, rapid CYP450 clearance, blood-brain barrier efflux, or hERG cardiotoxicity. Kerns and Di equip medicinal chemists to engineer balanced ADMET profiles early.
Connecting molecular target identification and pharmacophore modeling with preclinical safety pharmacology and IND regulatory filings, Poduri synthesizes the multidisciplinary stages required to advance a new chemical entity into human trials.
Focusing on the synthetic organic routes used to assemble commercial pharmaceuticals—heterocycles, asymmetric catalytic steps, and convergent couplings—Patrick shows how discovery synthesis transitions toward scalable process chemistry.
Crossing the valley of death from discovery candidate nomination to First-in-Human Phase I dosing requires salt selection, polymorph screening, impurity qualification, and GMP kilogram scale-up. Abdel-Magid and Caron detail these critical CMC handoffs.
Generative AI has reshaped de novo molecular design, and Sean Ekins walks computational chemists through diffusion models, reinforcement learning, and generative architectures for hit identification and multiparameter lead optimization.
DeepChem creators Ramsundar, Eastman, Walters, and Pande bridge deep learning architectures with molecular representation, graph neural networks, and biophysical modeling, giving computational chemists practical Python workflows for virtual screening and lead optimization.
G protein-coupled receptors remain the largest druggable target family. Terry Kenakin synthesizes modern biased agonism, allosteric modulation, and quantitative pharmacology assays to guide contemporary GPCR drug discovery.
Organizing drug design around neurotransmitter receptors, peptidergic hormones, ion channels, and second-messenger cascades, Nogrady and Weaver emphasize the biochemical physiology of target classes.
Embedded inside Vertex Pharmaceuticals as founder Joshua Boger raced to pioneer structure-based rational drug design against immunosuppressant and HIV protease targets, Werth captures the scientific drama and venture pressure of biotech discovery.
Tracing the discovery and clinical development of covalent BTK inhibitors Imbruvica (ibrutinib) and Calquence (acalabrutinib), Vardi exposes how small-molecule oncology breakthroughs navigate clinical trials, FDA scrutiny, and high-stakes biotech finance.
Table of Contents
Our mission

OpenCourser helps millions of learners each year. People visit us to learn workspace skills, ace their exams, and nurture their curiosity.

Our extensive catalog contains over 50,000 courses and twice as many books. Browse by search, by topic, or even by career interests. We'll match you to the right resources quickly.

Find this site helpful? Tell a friend about us.

Affiliate disclosure

We're supported by our community of learners. When you purchase or subscribe to courses and programs or purchase books, we may earn a commission from our partners.

Your purchases help us maintain our catalog and keep our servers humming without ads.

Thank you for supporting OpenCourser.

© 2016 - 2025 OpenCourser